NCT01438827View on ClinicalTrials.gov

Avanz Phleum Pratense Maintenance Dose

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

January 31, 2013

Conditions
Allergic Rhinoconjunctivitis
Interventions
DRUG

Avanz Phleum pratense

Suspension for Injection, Every 6 weeks for one year

DRUG

Placebo

Suspension for Injection, Every 6 weeks for one year

Trial Locations (1)

14050

UntersuchungsZentrum für Dermatologie, Allergologie und Asthma, Berlin

All Listed Sponsors
lead

ALK-Abelló A/S

INDUSTRY

NCT01438827 - Avanz Phleum Pratense Maintenance Dose | Biotech Hunter | Biotech Hunter